PBLA

Panbela Therapeutics, Inc. (PBLA) | Rumor.io

Panbela Therapeutics

PBLA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about PBLA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Mar 26

Panbela Therapeutics reported GAAP EPS of -$65.90, beating expectations by $151.10.
The company provided a business update and reported Q4 and FY 2024 financial results.
Panbela is expanding, making good decisions with patents and creating multiple revenue streams.

Generated by AI

Sentiment

Of the messages about PBLA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	100% +11.76
Bearish	—	—	0%	0% -11.76

Bullish· Feb 14

The company has a high price target of $25, according to Roth MKM, and a low float, making it a potentially volatile and attractive stock.
The stock is expected to experience significant growth, with some predicting a 1000% pump, driven by positive news and developments in the pancreatic cancer treatment space.
The stock has been seeing increased trading volume and is heating up, with some analysts and traders expecting it to break past $1.30 and continue to move upwards.

Bearish· Mar 7

Panbela Therapeutics, Inc. ($PBLA) has been delisted, with some users suggesting a group lawsuit for alleged scams and reverse splits.
The company's shares have been experiencing significant declines, with a 3.9% drop and a 38.74% decrease in value.
The bears have already won the battle for $PBLA, with some users predicting a further decline in the stock's value, potentially even to the OTC market.

Generated by AI

Topics

Of the messages about PBLA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	100%	100%	100%	66.67%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	33.33%

Announcements· Jan 30

Panbela Therapeutics, Inc. (PBLA) has had its Ivospemin (SBP-101) abstract accepted for a poster presentation at the American Association for Cancer Research (AACR) conference.
PBLA has undergone a 1:20 reverse stock split on January 18, resulting in a current outstanding share count of 450,000.
PBLA was mentioned in a news article discussing various companies presenting at a virtual investor conference, alongside ARVL and SONG.

Technical Analysis· Dec 19

$PBLA has a strong base of support in the 1.50 / 1.58 channel, with potential for momentum heading into market open.
The stock has a high spike of 150% and a change of 70% on day 1, with a 72% chance of a red close on day 2.
$PBLA has a solid fundamentals and strong chart indicators, with a potential break above 1.80 for a sharp upside.

Generated by AI

Community

Of the messages about PBLA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	47.28%
Newcomers	0%	0%	0%	52.72%

Regulars· Jan 30

Panbela Therapeutics, Inc. has had its Ivospemin (SBP-101) abstract accepted for a poster presentation at the American Association for Cancer Research (AACR) conference.
The company has undergone a 1:20 reverse stock split on January 18, with the current outstanding share count being 450,000.
Panbela Therapeutics, Inc.'s stock price has been trading at a volume 117% above average, with a recent decline of -7.43%.

Newcomers· Jan 29

The stock price of $PBLA rose significantly after the company exceeded enrollment targets in its pancreatic cancer trial.
Panbela Therapeutics has filed S-1/A forms with the SEC, indicating plans to raise funds through a public offering worth approximately $9M.
The company's decision to file the S-1/A forms may signal a change in the company's financial plans after a recent stock split.

Generated by AI

Also Discussed

Investors talking about PBLA also mention

#	Name	Attention
1	ZVSA - ZyVersa Therapeutics, Inc.	——
2	TCBP - TC Biopharm (Holdings) Plc	——
3	PaxMedica Inc.PXMD	0%0
4	C4 Therapeutics IncCCCC	0.01%new
5	NVOS - Novo Integrated Sciences, Inc.	——
6	Getaround, Inc.GETR	0%new
7	SMFL - Smart for Life, Inc.	——
8	ComSovereign Holding Corp.COMS	0%new
9	Minerva Surgical Inc.UTRS	0%0
10	Freight Technologies, Inc.FRGT	0%-0.01